PubMed:27172902 / 591-765
Annnotations
LitCoin-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 0-174 | Sentence | denotes | Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner. |
LitCoin-entities
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
11292 | 0-9 | ChemicalEntity | denotes | Cisplatin | MESH:D002945 |
11293 | 79-83 | GeneOrGeneProduct | denotes | CD80 | NCBIGene:12519 |
11294 | 85-89 | GeneOrGeneProduct | denotes | CD86 | NCBIGene:12524 |
11295 | 91-109 | GeneOrGeneProduct | denotes | MHC class I and II | NCBIGene:14961|NCBIGene:14972 |
LitCoin-GeneOrGeneProduct-v0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T17 | 0-9 | GeneOrGeneProduct | denotes | Cisplatin |
T18 | 27-36 | GeneOrGeneProduct | denotes | regulated |
T19 | 55-67 | GeneOrGeneProduct | denotes | cell surface |
T20 | 79-83 | GeneOrGeneProduct | denotes | CD80 |
T21 | 85-89 | GeneOrGeneProduct | denotes | CD86 |
T22 | 91-102 | GeneOrGeneProduct | denotes | MHC class I |
T23 | 107-109 | GeneOrGeneProduct | denotes | II |
T24 | 118-127 | GeneOrGeneProduct | denotes | regulated |
T25 | 147-151 | GeneOrGeneProduct | denotes | in a |
LitCoin-GeneOrGeneProduct-v2
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 0-9 | GeneOrGeneProduct | denotes | Cisplatin |
T10 | 55-67 | GeneOrGeneProduct | denotes | cell surface |
T11 | 79-83 | GeneOrGeneProduct | denotes | CD80 |
T12 | 85-89 | GeneOrGeneProduct | denotes | CD86 |
T13 | 91-102 | GeneOrGeneProduct | denotes | MHC class I |
LitCoin-GeneOrGeneProduct-v3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 79-83 | GeneOrGeneProduct | denotes | CD80 |
T6 | 85-89 | GeneOrGeneProduct | denotes | CD86 |
T7 | 91-102 | GeneOrGeneProduct | denotes | MHC class I |
LitCoin_Mondo_095
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T3 | 18-21 | DiseaseOrPhenotypicFeature | denotes | DCs | 0010155 |
LitCoin-Chemical-MeSH-CHEBI
Id | Subject | Object | Predicate | Lexical cue | ID: |
---|---|---|---|---|---|
T10 | 0-9 | ChemicalEntity | denotes | Cisplatin | http://purl.obolibrary.org/obo/CHEBI_27899 |
LitCoin-training-merged
Id | Subject | Object | Predicate | Lexical cue | ID: |
---|---|---|---|---|---|
T10 | 0-9 | ChemicalEntity | denotes | Cisplatin | http://purl.obolibrary.org/obo/CHEBI_27899 |
T7 | 91-102 | GeneOrGeneProduct | denotes | MHC class I | |
T51747 | 85-89 | GeneOrGeneProduct | denotes | CD86 | |
T63261 | 79-83 | GeneOrGeneProduct | denotes | CD80 |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 0-174 | Sentence | denotes | Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner. |
T4 | 0-174 | Sentence | denotes | Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner. |